DOP2011000329A - SOLID PREPARATION - Google Patents

SOLID PREPARATION

Info

Publication number
DOP2011000329A
DOP2011000329A DO2011000329A DO2011000329A DOP2011000329A DO P2011000329 A DOP2011000329 A DO P2011000329A DO 2011000329 A DO2011000329 A DO 2011000329A DO 2011000329 A DO2011000329 A DO 2011000329A DO P2011000329 A DOP2011000329 A DO P2011000329A
Authority
DO
Dominican Republic
Prior art keywords
solid preparation
dissolution
superior
symbol
iii
Prior art date
Application number
DO2011000329A
Other languages
Spanish (es)
Inventor
Wataru Hoshina
Makoto Fukuta
Shigeyuki Marunaka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43032637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2011000329(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of DOP2011000329A publication Critical patent/DOP2011000329A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporciona una preparación sólida que comprende (i) un compuesto representado por la fórmula (l): en la cual cada símbolo tiene la definición dada en la memoria descriptiva, o una sal de la misma; (ii) un alcohol de azúcar y (iii) un antagonista de calcio; la cual es superior en propiedad de disolución y estabilidad.A solid preparation is provided comprising (i) a compound represented by the formula (1): in which each symbol has the definition given in the specification, or a salt thereof; (ii) a sugar alcohol and (iii) a calcium antagonist; which is superior in property of dissolution and stability.

DO2011000329A 2009-04-30 2011-10-26 SOLID PREPARATION DOP2011000329A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009111381 2009-04-30
JP2010068625 2010-03-24

Publications (1)

Publication Number Publication Date
DOP2011000329A true DOP2011000329A (en) 2011-11-15

Family

ID=43032637

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2011000329A DOP2011000329A (en) 2009-04-30 2011-10-26 SOLID PREPARATION

Country Status (24)

Country Link
EP (1) EP2424501A2 (en)
JP (1) JP5666471B2 (en)
KR (1) KR101797776B1 (en)
CN (1) CN102481248B (en)
AU (1) AU2010242308A1 (en)
BR (1) BRPI1014388A2 (en)
CA (1) CA2760073A1 (en)
CL (1) CL2011002662A1 (en)
CO (1) CO6470841A2 (en)
CR (1) CR20110581A (en)
DO (1) DOP2011000329A (en)
EA (1) EA201171329A1 (en)
EC (1) ECSP11011494A (en)
GE (1) GEP20135940B (en)
IL (1) IL215962A0 (en)
MA (1) MA33280B1 (en)
MX (1) MX2011011011A (en)
MY (1) MY158158A (en)
NZ (1) NZ596395A (en)
PE (1) PE20120315A1 (en)
SG (1) SG175794A1 (en)
TW (1) TWI438201B (en)
WO (1) WO2010126168A2 (en)
ZA (1) ZA201108375B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL236001B1 (en) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Complex pharmaceutical composition comprising candesartan cilexetil and amlodipine, its preparation method and the unit dosage form comprising said composition,
KR101535586B1 (en) * 2014-08-01 2015-07-09 에스케이케미칼주식회사 Pharmaceutical preparation comprising amorphous or metastable form of rivaroxaban
KR101806004B1 (en) * 2015-01-30 2017-12-08 씨제이헬스케어 주식회사 A pharmaceutical composition comprising candesartan and amlodipine
CN106668016B (en) * 2015-11-11 2020-06-23 江苏先声药业有限公司 Solid preparation of azilsartan and amlodipine besylate composition and preparation method thereof
JP2017210435A (en) * 2016-05-25 2017-11-30 ダイト株式会社 Method for producing irbesartan and amlodipine besylate-containing tablet
JP2019001782A (en) * 2017-06-14 2019-01-10 東和薬品株式会社 Bilayer tablet
JP7101464B2 (en) * 2017-09-28 2022-07-15 エルメッド株式会社 A method for improving the quality of azilsartan or a salt thereof and amlodipine or a salt-containing tablet thereof, and azilsartan or a salt thereof and amlodipine or a salt-containing tablet thereof and a method for producing the same.
CN108210472A (en) * 2017-12-15 2018-06-29 蚌埠丰原医药科技发展有限公司 A kind of Cilnidipine solid dispersions tablet and preparation method thereof
CN108685925B (en) * 2018-05-15 2019-12-06 徐州医科大学 application of compound AB-38b in preparation of medicine for treating diabetic nephropathy
JP2020075869A (en) * 2018-11-05 2020-05-21 日本ケミファ株式会社 Tablet containing angiotensin ii receptor antagonist and calcium antagonist as active ingredients
JP7206872B2 (en) * 2018-12-07 2023-01-18 ニプロ株式会社 Pharmaceutical composition containing azilsartan and amlodipine and method for producing the same
JP2020090471A (en) * 2018-12-07 2020-06-11 ニプロ株式会社 Pharmaceutical composition containing azilsartan and amlodipine and method for producing the same
JP7441105B2 (en) 2020-03-31 2024-02-29 日本ジェネリック株式会社 Film-coated tablets containing azilsartan and amlodipine besilate

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2814513B2 (en) * 1988-02-03 1998-10-22 吉富製薬株式会社 Pharmaceutical composition with improved dissolution
JP3057471B2 (en) * 1993-06-07 2000-06-26 武田薬品工業株式会社 Agent for preventing or treating angiotensin II-mediated diseases
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
CA2416384A1 (en) 2000-07-17 2003-01-16 Takeda Chemical Industries, Ltd. Sulfone derivatives, their production and use
EP1369130A1 (en) * 2001-03-16 2003-12-10 Takeda Chemical Industries, Ltd. Process for producing sustained release preparation
EP1452176A4 (en) * 2001-12-03 2009-01-21 Takeda Pharmaceutical Insulin resistance improving agents
AU2003235395A1 (en) * 2002-05-22 2003-12-02 Shionogi And Co., Ltd. Pharmaceutical preparation improved in dissolving property of drug slightly soluble in water
WO2004048363A1 (en) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Imidazole derivative, process for producing the same, and use
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
CA2550012A1 (en) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same and use
TWI396686B (en) 2004-05-21 2013-05-21 Takeda Pharmaceutical Cyclic amide derivative, and its production and use
JP2006321726A (en) * 2005-05-17 2006-11-30 Sysmex Corp Method for controlling elution property of tablet
JP5148296B2 (en) * 2005-06-27 2013-02-20 第一三共株式会社 Angiotensin II receptor antagonist and pharmaceutical composition containing calcium antagonist
JP5063370B2 (en) * 2005-06-27 2012-10-31 第一三共株式会社 Method for preparing wet granulated pharmaceutical
DE102005031577A1 (en) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmaceutical dosage forms containing a combination of nifedipine and / or nisoldipine and an angiotensin II antagonist
MY149356A (en) * 2007-03-29 2013-08-30 Daiichi Sankyo Co Ltd Pharmaceutical composition
UY32126A (en) * 2008-09-25 2010-04-30 Takeda Pharmaceutical SOLID PHARMACEUTICAL COMPOSITION

Also Published As

Publication number Publication date
ZA201108375B (en) 2013-01-30
CN102481248B (en) 2013-12-11
GEP20135940B (en) 2013-10-10
CN102481248A (en) 2012-05-30
NZ596395A (en) 2013-06-28
SG175794A1 (en) 2011-12-29
CO6470841A2 (en) 2012-06-29
EA201171329A1 (en) 2012-05-30
MA33280B1 (en) 2012-05-02
CL2011002662A1 (en) 2012-06-15
WO2010126168A3 (en) 2011-03-03
WO2010126168A2 (en) 2010-11-04
CA2760073A1 (en) 2010-11-04
MY158158A (en) 2016-09-15
TWI438201B (en) 2014-05-21
KR20120026060A (en) 2012-03-16
EP2424501A2 (en) 2012-03-07
JP5666471B2 (en) 2015-02-12
ECSP11011494A (en) 2011-12-30
KR101797776B1 (en) 2017-11-14
BRPI1014388A2 (en) 2016-04-05
AU2010242308A1 (en) 2011-12-01
MX2011011011A (en) 2011-11-02
IL215962A0 (en) 2012-01-31
TW201041873A (en) 2010-12-01
JP2012525323A (en) 2012-10-22
PE20120315A1 (en) 2012-04-07
CR20110581A (en) 2012-01-19

Similar Documents

Publication Publication Date Title
DOP2011000329A (en) SOLID PREPARATION
DK2068822T3 (en) Self-preserved aqueous pharmaceutical compositions
UY29857A1 (en) DERIVATIVES OF 4-AMINO-QUINAZOLINA, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS.
CL2008003684A1 (en) Pharmaceutical composition comprising an aluminum salt, having a molar ratio of aluminum to chloride from about 0.3: 1 to 3: 1, further comprising zirconium; method of preparing the composition; use as an antiperspirant.
BR112012004335A2 (en) compound, pharmaceutical composition, and use of the compound.
EA200702352A1 (en) NEW NUTRITSEVTIK COMPOSITIONS
ECSP10010347A (en) (R) -2- (4-CYCLOPROPANSULPHONYL-PHENYL) -N-PIRAZIN-2-IL-3- (TETRAHYDROPIRAN-4-IL) -PROPIONAMIDE CRYSTALLINE
ECSP088716A (en) MEDICINES CONTAINING FLUOROQUINOLONES
ECSP11011001A (en) SOLID PHARMACEUTICAL COMPOSITION
NI201100149A (en) DERIVATIVES OF TIADIAZOLES AND OXADIAZOLES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY.
AR093738A1 (en) SOLID FORMS INCLUDING INHIBITORS OF NS5A HCV, ITS COMPOSITIONS AND ITS USES
BRPI0911772A2 (en) compound, pharmaceutical composition, and use of the compound.
DE602006006016D1 (en) Preparation of epoxy-containing aqueous compositions
ECSP11010856A (en) SOLID PHARMACEUTICAL COMPOSITION
EA200900780A1 (en) EPOTHILON ANALOGUES MODIFIED IN C12-C13 PROVISIONS AS ANTICATIVE MEDICINES
CO6400226A2 (en) ANTI-INFLAMMATORY MICROLID
BR112012002311A2 (en) compound, pharmaceutical composition, and use of the compound.
AR063597A1 (en) NEW SALT
ATE537816T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING LEFLUNOMIDE
RU2007112594A (en) HYALURONIC ACID DERIVATIVES WITH REDUCED BIODEGRADABILITY
BRPI0811431A2 (en) Aqueous pharmaceutical composition.
ECSP088574A (en) DERIVATIVES OF 2-CARBAMIDA-4-FENILTIAZOL, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
EA200702590A1 (en) INHIBITORS OF SOLUBLE ADENYLACYCLIC
BRPI0809728A2 (en) "Substituted sulfonamides, preparation process, pharmaceutical composition, as well as their use."
AR109745A2 (en) DERIVATIVE OF 4-PYRIMIDINSULFAMIDE